Cargando…
TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension
BACKGROUND: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this study, we aimed at exploring and validating the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210142/ https://www.ncbi.nlm.nih.gov/pubmed/32395481 http://dx.doi.org/10.21037/atm.2020.03.176 |
_version_ | 1783531220205830144 |
---|---|
author | He, Fazhong Sun, Bao Li, Ling Liu, Mouze Lin, Weijie Liu, Lin Sun, Yinxiang Luo, Yuhong Wu, Lin Lu, Ligong Zhang, Wei Zhou, Zhiling |
author_facet | He, Fazhong Sun, Bao Li, Ling Liu, Mouze Lin, Weijie Liu, Lin Sun, Yinxiang Luo, Yuhong Wu, Lin Lu, Ligong Zhang, Wei Zhou, Zhiling |
author_sort | He, Fazhong |
collection | PubMed |
description | BACKGROUND: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this study, we aimed at exploring and validating the effect of TRIB3 polymorphism on antihypertensive drugs responses. METHODS: A total of 830 hypertensive patients, who were administered with open-labeled hydrochlorothiazide (12.5 mg once daily) and randomly assigned to off-labeled felodipine (5 mg) or a matched placebo combination treatment (1:1), were selected from the Felodipine Event Reduction (FEVER) study. A strategy of screening 259 samples and validating the remaining 531 samples was implemented. Four functional SNPs were selected (rs2295490, rs11470129, rs4815567 and rs6037475 in TRIB3). A mixed linear model was performed to analyze the effects of TRIB3 SNPs on antihypertensive drugs responses. RESULTS: We found that TRIB3 rs6037475 CC genotype was associated with a reduction of diastolic blood pressure (DBP) (P=6.3×10(−3)) in the felodipine treatment group of screening set, and was also associated with a reduction of systolic blood pressure (SBP) (P=0.021), DBP (P=6.0×10(−3)) and mean arterial pressure (MAP) (P=0.021) in the felodipine treatment group of the validation set. As for the reductions influenced by the rs2295490, rs11470129 and rs4815567 genetic variations, however, the adjusted P-value did not reach statistical significance. Combined screening and validation set analysis found that patients with TRIB3 rs6037475 CC genotype had a significant higher mean SBP, DBP and MAP than those with TT genotype in the felodipine treatment group (CC vs. TT −10.2±0.74 vs. −17.8±0.21, P=7.8×10(−3); −4.6±0.50 vs. −10.2±0.23, P=3.0×10(−4); −6.5±0.54 vs. −12.7±0.14, P=3.0×10(−4), respectively). CONCLUSIONS: These results suggest that TRIB3 rs6037475 genetic variation can be useful as a bio-marker for predicting felodipine drug response in Chinese patients with hypertension. |
format | Online Article Text |
id | pubmed-7210142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-72101422020-05-11 TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension He, Fazhong Sun, Bao Li, Ling Liu, Mouze Lin, Weijie Liu, Lin Sun, Yinxiang Luo, Yuhong Wu, Lin Lu, Ligong Zhang, Wei Zhou, Zhiling Ann Transl Med Original Article BACKGROUND: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this study, we aimed at exploring and validating the effect of TRIB3 polymorphism on antihypertensive drugs responses. METHODS: A total of 830 hypertensive patients, who were administered with open-labeled hydrochlorothiazide (12.5 mg once daily) and randomly assigned to off-labeled felodipine (5 mg) or a matched placebo combination treatment (1:1), were selected from the Felodipine Event Reduction (FEVER) study. A strategy of screening 259 samples and validating the remaining 531 samples was implemented. Four functional SNPs were selected (rs2295490, rs11470129, rs4815567 and rs6037475 in TRIB3). A mixed linear model was performed to analyze the effects of TRIB3 SNPs on antihypertensive drugs responses. RESULTS: We found that TRIB3 rs6037475 CC genotype was associated with a reduction of diastolic blood pressure (DBP) (P=6.3×10(−3)) in the felodipine treatment group of screening set, and was also associated with a reduction of systolic blood pressure (SBP) (P=0.021), DBP (P=6.0×10(−3)) and mean arterial pressure (MAP) (P=0.021) in the felodipine treatment group of the validation set. As for the reductions influenced by the rs2295490, rs11470129 and rs4815567 genetic variations, however, the adjusted P-value did not reach statistical significance. Combined screening and validation set analysis found that patients with TRIB3 rs6037475 CC genotype had a significant higher mean SBP, DBP and MAP than those with TT genotype in the felodipine treatment group (CC vs. TT −10.2±0.74 vs. −17.8±0.21, P=7.8×10(−3); −4.6±0.50 vs. −10.2±0.23, P=3.0×10(−4); −6.5±0.54 vs. −12.7±0.14, P=3.0×10(−4), respectively). CONCLUSIONS: These results suggest that TRIB3 rs6037475 genetic variation can be useful as a bio-marker for predicting felodipine drug response in Chinese patients with hypertension. AME Publishing Company 2020-04 /pmc/articles/PMC7210142/ /pubmed/32395481 http://dx.doi.org/10.21037/atm.2020.03.176 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article He, Fazhong Sun, Bao Li, Ling Liu, Mouze Lin, Weijie Liu, Lin Sun, Yinxiang Luo, Yuhong Wu, Lin Lu, Ligong Zhang, Wei Zhou, Zhiling TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension |
title | TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension |
title_full | TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension |
title_fullStr | TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension |
title_full_unstemmed | TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension |
title_short | TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension |
title_sort | trib3 rs6037475 is a potential biomarker for predicting felodipine drug response in chinese patients with hypertension |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210142/ https://www.ncbi.nlm.nih.gov/pubmed/32395481 http://dx.doi.org/10.21037/atm.2020.03.176 |
work_keys_str_mv | AT hefazhong trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT sunbao trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT liling trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT liumouze trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT linweijie trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT liulin trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT sunyinxiang trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT luoyuhong trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT wulin trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT luligong trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT zhangwei trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension AT zhouzhiling trib3rs6037475isapotentialbiomarkerforpredictingfelodipinedrugresponseinchinesepatientswithhypertension |